News

May 21, 2020May 21, 2020

Annamycin Trial in Poland Permitted to Accelerate Dose Escalation in AML Patients

News

The Polish Department of Registration of Medicinal Products (URPL) has granted Moleculin Biotech permission to accelerate the dose-escalation portion of a Phase 1/2 clinical trial of Annamycin, which is ... Read more

May 21, 2020May 21, 2020

Video Games Connect Chronically Ill Children Isolated at Home, Hospital

cystic fibrosis, News, syndicated

Dara Riva always had a rule that her 10-year-old son could play video games only once a week. But then the COVID-19 pandemic struck, and her perspective changed. Riva’s ... Read more

May 14, 2020May 14, 2020

Phase 3 Trial Stops Testing Idasanutlin in AML Patients Undergoing Chemo

News

Roche has removed idasanutlin (RG7388), an investigational anti-cancer agent, from its Phase 3 MIRROS trial that was assessing the effectiveness of the medication when used in combination with chemotherapy ... Read more

May 7, 2020May 7, 2020

FDA Reviewing CC-486 as Maintenance Treatment of Adult Patients in Remission

News

The U.S. Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s application for CC-486 as a maintenance treatment for adults with acute myeloid leukemia (AML) who achieved complete ... Read more

April 30, 2020April 30, 2020

GT Biopharma Completes Dosing of First Patient in Phase 1/2 Trial of GTB-3550

News

GT Biopharma has successfully completed dosing of the first patient participating in its Phase 1/2 clinical trial of GTB-3550 (OXS-3550), the company’s experimental treatment for relapsed or refractory acute ... Read more

April 23, 2020April 23, 2020

Antibody to Treat AML Showing Safety and Clinical Activity in Early Trial Data

News

APVO436, an investigational therapy for acute myeloid leukemia (AML) and high-grade myelodysplastic syndrome (MDS), is showing safety and evidence of clinical activity in these patients, according to preliminary data from ... Read more

April 16, 2020April 16, 2020

COVID-19 Pandemic Stops Phase 2 Trial of Ficlatuzumab Combo Therapy for AML

News

The Phase 2 CyFi-2 study assessing the safety and efficacy of ficlatuzumab (previously AV-299) combined with standard chemotherapy in patients with hard-to-treat acute myeloid leukemia (AML) has been discontinued ... Read more

April 9, 2020April 9, 2020

FDA Grants Orphan Drug Status to SEL120 for Acute Myeloid Leukemia

News

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Ryvu Therapeutics’ oral inhibitor SEL120 for treating people with acute myeloid leukemia (AML). In the U.S., ... Read more

April 2, 2020April 2, 2020

Cancer Vaccine Galinpepimut-S Prolongs Life of Patients with AML, Results of Pilot Trial Show

News

Second-line maintenance therapy with the experimental vaccine galinpepimut-S (GPS) significantly prolongs the life of patients with acute myeloid leukemia (AML) who are on their second remission of the disease, ... Read more

April 2, 2020April 2, 2020

NORD’s Advice on COVID-19: You’re Stronger Than You Think

News

First, the bad news: If you’re one of the 30 million or so Americans with a rare disease, you probably have lower immunity to the novel coronavirus than most ... Read more

Pin It on Pinterest